Department of Pulmonology, Isala, Dr. van Heesweg 2, 8025AB Zwolle, The Netherlands.
Department of Pulmonology, Isala, Dr. van Heesweg 2, 8025AB Zwolle, The Netherlands.
Thromb Res. 2017 Aug;156:172-176. doi: 10.1016/j.thromres.2017.06.024. Epub 2017 Jun 23.
Despite growing evidence on safe and feasible outpatient treatment for acute pulmonary embolism (PE), the majority of patients is still treated in an inpatient setting. This is probably due to a lack of clear guidelines on this subject.
To evaluate safety and patient reported outcome measures (PROM) on outpatient treatment of acute PE.
We conducted a prospective cohort study. 250 patients presenting with acute PE and Pulmonary Embolism Severity Index (PESI) class I or II were enrolled. Safety of outpatient treatment was assessed by measuring all-cause mortality, recurrent venous thromboembolism (VTE) and episodes of relevant bleeding, with a follow-up period of four weeks and six months. Additionally, PROM's on outpatient treatment were evaluated by repeatedly measuring VAS-scores for pain and dyspnea during the recovery, and by assessing the improvement in SF-36 scores between admission and after six months.
We found an all-cause mortality rate of 0.4% (95% CI 0.07-2.23), rate of recurrent VTE of 0% (95% CI 0-1.51) and rate of relevant bleeding episodes of 6.4% (95% CI 3.98-10.14). VAS-scores improved significantly during the first 24-h after admission, and continued to improve significantly after five days of home treatment. SF-36 scores on 6 out of 8 domains improved significantly between admission and after six months.
Our study shows that outpatient treatment is safe in selected low-risk patients based on their PESI score. Additionally, our data on patient reported outcome measures support the presumption of a good course of recovery during outpatient treatment.
尽管有越来越多的证据表明急性肺栓塞(PE)的门诊治疗安全且可行,但大多数患者仍在住院治疗。这可能是由于缺乏关于这一主题的明确指南。
评估急性 PE 门诊治疗的安全性和患者报告的结果测量(PROM)。
我们进行了一项前瞻性队列研究。共纳入 250 例急性 PE 患者和肺栓塞严重指数(PESI)I 级或 II 级患者。通过测量所有原因死亡率、复发性静脉血栓栓塞(VTE)和相关出血事件来评估门诊治疗的安全性,随访时间为四周和六个月。此外,通过反复测量恢复过程中疼痛和呼吸困难的 VAS 评分,以及评估 SF-36 评分在入院和六个月后的改善情况,评估门诊治疗的 PROM。
我们发现全因死亡率为 0.4%(95%CI 0.07-2.23),复发性 VTE 率为 0%(95%CI 0-1.51),相关出血事件发生率为 6.4%(95%CI 3.98-10.14)。入院后 24 小时内 VAS 评分显著改善,在家治疗 5 天后继续显著改善。SF-36 评分在 8 个领域中有 6 个在入院和六个月后显著改善。
我们的研究表明,根据 PESI 评分,门诊治疗在选定的低危患者中是安全的。此外,我们关于患者报告结果测量的数据支持在门诊治疗期间恢复良好的假设。